Introduction
============

The incidence of head and neck squamous cell carcinoma is generally decreasing \[[@B1],[@B2]\], likely due to declining rates of smoking and alcohol use. An exception to this trend has been cancers affecting the oropharynx, which have increased by more than two-fold in some countries over the last three decades \[[@B3],[@B4]\]. Infection by human papillomavirus (HPV) has been implicated as the cause of this dramatic rise in oropharyngeal squamous cell carcinomas (OPSCC), particularly those affecting the palatine and lingual tonsils \[[@B3]\]. Importantly, numerous studies have reported improved survival for patients with HPV-positive tumors \[[@B3],[@B5],[@B6]\]. Of the several high-risk strains of HPV identified, approximately 90 percent of HPV-positive OPSCC is attributed to type 16, while other types are rare \[[@B7]\].

There is a wide discrepancy in the fraction of OPSCC that are HPV-positive world-wide, with incidence rates ranging from 11% to as high as 93% \[[@B4],[@B8]\]. In North America, most reports suggest that the incidence is approximately 60 percent \[[@B5],[@B6]\]. These differences may be attributed to geographic population-based differences, as well as the varying sensitivity and specificity of different detection methods for the presence of HPV. We endeavoured to study patients from our catchment area in Southwestern Ontario, Canada to determine the incidence of HPV-related OPSCC and confirm whether HPV status conferred a survival advantage.

Methods
=======

Study population
----------------

Study approval was obtained from the University of Western Ontario Research Ethics Board. A retrospective search of the London Regional Cancer Program (LRCP) database was performed to identify patients diagnosed with OPSCC from 2003 to 2009. Patient eligibility required: 1) a histologically confirmed diagnosis of squamous cell carcinoma, 2) no prior history of head and neck cancer, and 3) the availability of a pre-treatment primary site biopsy specimen for analysis. Patient data was extracted from a retrospective chart review, which included age at diagnosis, use of tobacco and alcohol, AJCC TNM stage, treatment regimen, and post-treatment follow-up information.

After the completion of cancer therapy, patients were followed closely at six to twelve week intervals by either a radiation oncologist or head and neck surgeon. Treatment response was evaluated by physical exam as well as computed tomography imaging as needed. Salvage neck dissection was undertaken within three months of the completion of radiation treatment if evidence of residual adenopathy was present radiographically or on physical exam. The presence of neck disease more than three months after diagnosis was considered a regional persistence.

Deparaffinization
-----------------

The formalin fixed paraffin embedded blocks from each patient's primary site were sectioned (5 μm thick) and mounted on slides. The slides were then deparaffinized with 3 minute washes in xylene (100%) twice, followed by a 1:1 xylene:ethanol mix, then ethanol (100%) twice, followed by single washes in ethanol at 95%, 70% and 50%. Lastly, the slides were washed in water for 5 minutes.

p16 immunohistochemistry
------------------------

Citrate buffer was applied to the deparaffinized slides for heat induced epitope retrieval for 30 minutes, followed by treatment with 0.1% Triton X-100 in PBS. Endogenous biotin was quenched using an avidin/biotin kit (Biocare Medical, Concord CA,USA) and the endogenous peroxidase activity was blocked by H~2~0~2~ prior to primary antibody incubation. Specimens were incubated with a primary mouse monoclonal antibody against human p16 (MTM Laboratoris, Heidelberg, Germany) at 1:500 dilution. The Vectastain ABC kit, with a goat anti mouse secondary antibody, was used as per the manufacturer's instructions. Antigen detection was done using diaminobenzidine chromogen (Biocare Medical, Concord, CA). Tissues were counterstained with Carazzi's hematoxylin. Immunohistochemistry scoring was conducted by two head and neck pathologists (KK and BW) blinded to HPV status and patient outcome. Scoring was as described by Begum et al., with strong and diffuse staining (\>80 percent of tumour cells) regarded as a positive result, and negative if absent or focal \[[@B9]\].

DNA extraction
--------------

Deparaffinized tissue was scraped into a 1.5 ml eppendorf tube containing 50--100 μl (depending on the amount of tissue) of TE and proteinase K (final concentration 2 mg/ml) and incubated overnight at 65°C. Following proteinase K treatment, the samples were heated at 95°C for 10 minutes and allowed to cool to room temperature. 0.2 μl of each sample was used directly in the qPCR reactions.

High-risk HPV detection by multiplex qPCR
-----------------------------------------

In an effort to screen clinical samples for the presence of human papillomavirus (HPV), we designed a multiplex quantitative PCR to identify those samples that were HPV positive and to confirm the HPV type in the positive samples. We designed primer/probe sets (Table [1](#T1){ref-type="table"}) against a 115 nucleotide (nt) fragment within exon 6 of GAPDH (internal control), a 110 nt region across E6-E7 of HPV-16, a 137 nt fragment across the HPV-18 E6-E7 region, and a 100 nt fragment across a region of E1 that had a high degree of homology to high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. The multiplex PCR reactions were run on a Stratagene Mx3000P instrument using the conditions recommended in the Quantitech Multiplex handbook (Qiagen). Twenty μl reactions were heated for 15 minutes at 95°C to activate the amplification enzyme. This was followed by 40 cycles of 94°C for 60 seconds and 60°C for 90 seconds. Standard curves were produced from 10 fold serial dilutions of CaSki cell genomic DNA. Caski cell DNA was used as a positive control for HPV16 and HeLa cell genomic DNA was used as the HPV18 control. All samples were first tested with the type 16 and 18 primer/probe sets. Samples that were negative for types 16 and 18 were then tested with the broad-spectrum primer/probe set to detect the presence of other high-risk HPV types.

###### 

PCR primers for HPV testing

  **Name**                 **Sequence 5′ to 3′**
  ------------------------ ----------------------------------------------------
  GAPDH Forward            GCTCATTTGCAGGGGGGAGCC
  GAPDH Reverse            CTGATGATCTTGAGGCTGTTG
  GAPDH Probe              CY5-TCTGCCCCCTCTGCTGATGCCCCCATGTTCGTCATGGGA --BHQ2
  HPV 16 Forward           TTGCAGATCATCAAGAACACGTAGA
  HPV 16 Reverse           GTAGAGATCAGTTGTCTCTGGTTGC
  HPV 16 Probe             JOE-AATCATGCATGGAGATACACCTACATTGCATGA --BHQ1
  HPV 18 Forward           CAACCGAGCACGACAGGAACG
  HPV 18 Reverse           TAGAAGGTCAACCGGAATTTTCAT
  HPV 18 Probe             ROX-AATATTAAGTATGCATGGACCTAAGGCAACATTGCAA --BHQ2
  HPV all Forward (E1)     CCTATAGTACATTTAAAAGGTG
  HPV all Reverse (E1)     CNTGTCCAATGCCAGGTAGATG
  HPV all Probe (E1)       FAM-AATAGTTTAAAATGTTTAAGATATAG-BHQ1
  HPV other Forward (E2)   GCATTATATTGGTATAGAACAGG
  HPV other Reverse (E2)   TCATTRTCASATGCCCATTGYACC

*HPV* human papillomavirus; *R* puRine (A or T); *S* Strong (C or G); *Y* pYrimidine (C or T).

High-risk HPV detection by conventional PCR
-------------------------------------------

Tumors that tested positive for HPV infection by qPCR with the broad spectrum primer/probe set designed against the E2 region of HPV were tested with a second broad spectrum set of primers against the E1 region of HPV by conventional PCR (Table [1](#T1){ref-type="table"}). PCR reactions (20 μl) were prepared using 0.2 μl of patient template DNA and amplified with Phusion DNA polymerase (Fisher Scientific, Toronto, Canada) following a hotstart (98°C for 30 sec followed by 37 cycles of 98°C for 10 sec, 55°C for 10 sec, 72°C for 30 sec). Amplified products were resolved on 1% agarose gels. Bands of interest were extracted from agarose gel slices, purified on columns (Bio Basic, Markham, Canada) and sequenced with the appropriate primer. Results were used to query the Genbank Database to identify the corresponding HPV type.

Statistical analysis
--------------------

Statistical analysis was performed using SPSS with the exact tests package (IBM, Armonk, NY). For all analyses, a *p* value of 0.05 or less was considered statistically significant. Patient variables were compared using the Fisher exact test. Disease-free survival (DFS) was defined as the time of completion of treatment to local, regional, or distant recurrence. Survival curves were created using the method of Kaplan and Meier. The Cox proportional hazard model was used to estimate the relative hazard of mortality or recurrence over the follow-up period and to perform univariate and multivariate analysis. Multivariate analysis began with a fit to all patient variables, followed by backward stepwise regression using the Akaike information criterion (stepAIC function) and retention of variables in the final model having *p* values of 0.05 or less.

Results
=======

HPV-16 presents more frequently with neck metastases than other high-risk HPV types
-----------------------------------------------------------------------------------

A total of 95 patients with OPSCC were identified. The majority of patients were treated with organ preservation strategies (86/95, 90.5%) as opposed to primary surgery (9/95, 9.5%) (Table [2](#T2){ref-type="table"}). Patients only underwent primary surgery if they refused primary radiation (2), had gross bony involvement on imaging (5) or had medical contraindications to radiation (2, severe scleroderma). Fifty-nine patients had tumour biopsy specimens that were p16 positive. Real-time qPCR for high-risk HPV types clearly separated HPV-positive tumors (all had a cycle threshold C~T~ \< 30) and negative tumors (C~T~ \> 35). Overall, fifty tumors were positive for HPV, including 45 positive for HPV-16 (90%) and 2 positive for HPV-18. The broad-spectrum primer/probe set detected three other HPV-positive tumors, which were determined to be type 33 (1 tumor) and type 67 (2 tumors) by sequencing of PCR products. The identification of HPV-67 was surprising because the high-risk HPV-67 sequence was not included in our efforts to design broad-spectrum primers. Regardless, sequencing of the 150 nt product was highly consistent with the published HPV-67 sequence by BLAST analysis \[[@B10]\] (p \< 10^-39^, accession D21208). p16-positivity was tightly correlated with HPV status (*p* \< 0.0001, Fishers exact test), further supporting its use as a surrogate marker of HPV infection. Analysis of patient characteristics and HPV-positive OPSCC revealed associations with age \<60, tonsil or base of tongue primary site, and minimal smoking history (*p* \< 0.05, Table [2](#T2){ref-type="table"}). Patients with HPV-16-positive tumors were compared to those with tumors positive for other high-risk HPV types. HPV-16-positive tumors were significantly more likely to have neck metastases (43/45 versus 2/5, *p* = 0.005, Table [3](#T3){ref-type="table"}). One of two HPV-18-positive patients and one of two HPV-67-positive patients had lymph node involvement. The sole HPV-33-positive patient was node negative.

###### 

Correlation of HPV status with patient and tumor factors

                                               **All high-risk HPV**   **HPV-16 only**                          
  ---------------------- --------------- ---- ----------------------- ----------------- ------------- ---- ---- -------------
         **Age**              \<60        51            16                   35          **\<0.001**   18   33   **\<0.001**
         \> = 60               44         29            15                                   32        12       
        **Gender**            Male        75            32                   43             0.08       37   38      0.32
          Female               20         13             7                                   13        7        
       **Subsite**           Tonsil                     21                   31           **0.02**     23   29    **0.01**
      Base of Tongue                      10            15                                   12        13       
          Other                           14             4                                   15        3        
   **T Classification**         1         14             4                   10             0.27       4    10      0.19
            2                  25         11            14                                   14        11       
            3                  30         18            12                                   19        11       
            4                  26         12            14                                   13        13       
   **N Classification**         0         18            13                    5             0.09       16   2     **0.002**
            1                  13         7              6                                    8        5        
            2                  54         21            33                                   22        32       
            3                  10         4              6                                    4        6        
     **Overal Stage**           1         2              1                    1             0.49       1    1     **0.02**
            2                   9         5              4                                    8        1        
            3                  13         8              5                                   10        4        
            4                  71         31            40                                   31        39       
       **Smoking**        never smokers   20             4                   16           **0.006**    5    1     **0.001**
          1-9 py                6         2              4                                    2        4        
         10-19 py               6         1              5                                    1        5        
         \>20 py               57         35            22                                   39        18       
         Unknown                6         3              3                                    3        3        
       **Alcohol**        \< 21 drinks    70            30                   40             0.37       34   36      0.45
     **(drinks/wk)**       \>21 drinks    17            10                    7                        11   6          
         Unknown                8         5              3                                    5        3        
      **Treatment**            CRT        62            29                   33             0.78       30   32      0.55
        Radiation              11         5              6                                    8        3        
     Induction + CRT           13         5              8                                    6        7        
      Surgery + CRT             5         3              2                                    3        2        
       Surgery + RT             2         1              1                                    1        1        
         Surgery                2         2              0                                    2        0        
       **HPV Type**            16         45             0                   45                        0    45         
            18                  2         0              2                                    2        0        
            33                  1         0              1                                    1        0        
            67                  2         0              2                                    2        0        
         **p16**            Negative      35            34                    1          **\<0.001**   34   1    **\<0.001**
         Positive              59         10            49                                   15        44       

*HPV* human papillomavirus, *py* pack years, *RT* radiation, *CRT* chemoradiation.

\* Fisher exact test.

###### 

Comparison of HPV-16 and other high-risk (non-16) HPV types

                                               **HPV-Positive**       
  ---------------------- --------------- ---- ------------------ ---- -------------
         **Age**              \<60        35          2           33      0.15
         \> = 60               15         3           12              
        **Gender**            Male        43          5           38        1
          Female                7         0           7               
       **Subsite**           Tonsil       31          2           29      0.33
      Base of Tongue           15         2           13              
          Other                 4         1           3               
   **T Classification**         1         10          0           10      0.58
            2                  14         3           11              
            3                  12         1           11              
            4                  14         1           13              
   **N Classification**         0         5           3           2     **0.005**
           1-3                 45         2           43              
     **Overal Stage**           1         1           0           1    **\<0.001**
            2                   4         3           1               
            3                   5         1           4               
            4                  40         1           39              
       **Smoking**        never smokers   16          1           15      0.73
          1-9 py                4         0           4               
         10-19 py               5         0           5               
         \>20 py               22         4           18              
         Unknown                3         0           3               
       **Alcohol**        \< 21 drinks    40          4           36      0.69
     **(drinks/wk)**       \>21 drinks    7           1           6          
         Unknown                3         0           3               
      **Treatment**            CRT        33          1           32    **0.02**
        Radiation               6         3           3               
     Induction + CRT            8         1           7               
      Surgery + CRT             2         0           2               
       Surgery + RT             1         0           1               
         Surgery                0         0           0               
         **p16**            Negative      1           0           1         1
         Positive              49         5           44              

*HPV* human papillomavirus, *py* pack years, *RT* radiation, *CRT* chemoradiation.

\* Fisher exact test.

HPV-positive patients experience improved survival
--------------------------------------------------

Median follow-up time for the study was 39 months (range: 1 to 91 months). A total of 26 of 95 patients (27%) recurred, and eleven (42%) of these patients died of disease. Five patients died of other causes. The three-year disease-free (DFS) and overall survival (OS) for all patients was 75 % and 85%, respectively. Univariate analysis identified age, p16 status and the presence of any high-risk HPV type as predictors of disease-free and overall survival (Table [4](#T4){ref-type="table"} and Figure [1](#F1){ref-type="fig"}A and [1](#F1){ref-type="fig"}B). Three year DFS and OSP rates for patients with HPV-positive versus HPV-negative tumors were 85% vs 49%, and 90% vs 65%; respectively. p16 positivity was also associated with improved DFS and OS (p \< 0.05, Table [4](#T4){ref-type="table"} and Figure [1](#F1){ref-type="fig"}C and [1](#F1){ref-type="fig"}D). Multivariate analysis revealed high-risk HPV infection as the only independent predictor of disease-free and overall survival (p = 0.001 and p = 0.004, respectively, Table [4](#T4){ref-type="table"}). As multiple treatments were used, we repeated the survival analysis using only the data from the sixty-two patients that received platinum-based concurrent chemoradiation to remove this potential confounding factor. High-risk HPV infection once again was the only predictor of overall and disease-free survival (p \< 0.005, data not shown).

###### 

Univariate and multivariate relations to disease free survival

                                                                **DFS (Univariate analysis)**   **DFS (Multivariate analysis)**                      
  ------------------- ---------------------------------------- ------------------------------- --------------------------------- ------------------- -------------
          Age                     \> = 60 vs \<60                     3.34 (1.44-7.71)                     **0.01**                                         
          Sex                      Male vs Female                     1.06 (0.40-2.81)                       0.91                                           
         Site                   Tonsil, BOT vs Other                                                                                                        
        T stage                      3,4 vs 1,2                       1.00 (0.46-2.17)                       0.99                                           
        N stage                      N + vs N0                        0.51 (0.22-1.18)                       0.11                                           
        Smoking            \>10 py vs \< 10 py or unknown             1.54 (0.64-3.72)                       0.34                                           
        Alcohol        \>21 drinks vs \<21 drinks and Unknown         0.94 (0.33-2.75)                       0.92                                           
          p16                   Positive vs Negative                  0.41 (0.19-0.90)                     **0.025**                                        
   All High-Risk HPV            Positive vs Negative                  0.25 (0.11-0.58)                     **0.001**              0.24 (0.10-0.56)     **0.001**
      HPV 16 only               Positive vs Negative                  0.27 (0.11-0.65)                     **0.003**                                        
                                                                **OS (Univariate Analysis)**    **OS (Multivariate Analysis)**                       
                                                                      **HR (95% CI)\***                   ***P\*\****             **HR (95% CI)\***   ***P\*\****
          Age                     \> = 60 vs \<60                     3.05 (1.06-8.80)                     **0.04**                                         
          Sex                      Male vs Female                     0.70 (0.23-2.17)                       0.53                                           
         Site                   Tonsil, BOT vs Other                  1.38 (0.39-4.90)                       0.61                                           
        T stage                      3,4 vs 1,2                       1.76 (0.61-5.07)                       0.30                                           
        N stage                      N + vs N0                        0.37 (0.13-1.01)                       0.05                                           
        Smoking            \>10 py vs \< 10 py or unknown             2.34 (0.67-8.25)                       0.19                                           
        Alcohol        \>21 drinks vs \<21 drinks and Unknown         1.16 (0.33-4.09)                       0.81                                           
          p16                   Positive vs Negative                  0.24 (0.09-0.67)                     **0.006**                                        
   All High-Risk HPV            Positive vs Negative                  0.20 (0.06-0.62)                     **0.005**              0.19 (0.06-0.60)     **0.004**
      HPV 16 only               Positive vs Negative                  0.17 (0.05-0.59)                     **0.006**                                        

*DFS* disease-free survival, *OS* overal survival, *HR* hazard ratio, *CI* confidence interval, *py* pack years, *HPV* human papillomavirus.

\*CI (confidence interval) by Cox proportional hazard analysis.

\*\*Wald test.

![Disease-free and overall survival by HPV status (A and B) and p16 status (C and D).](1916-0216-42-9-1){#F1}

Seven of 45 HPV-16-positive patients recurred, while none of the five patients with tumors due to non-16 high-risk HPV types developed a recurrence (DFS 83.3% vs 100%, p = 0.94, Figure [2](#F2){ref-type="fig"}A). No difference in overall survival between the HPV-16 and the HPV-other high-risk group was detected (Figure [2](#F2){ref-type="fig"}B). The only death in the patients with non-16 HPV-positive tumors was due to a myocardial infarction in an 87-year-old patient 13 months after diagnosis. Together, these data confirm the significance of HPV as a prognostic factor in OPSCC, and suggests that stage at presentation may differ between high-risk HPV types.

![Disease-free (A) and overall survival (B) for HPV-positive patients stratified by HPV type.](1916-0216-42-9-2){#F2}

Discussion
==========

Recent studies have clearly described the current epidemic of HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) in North America and beyond \[[@B3],[@B4]\]. Using tumors from patients from three American population based cancer registries in the Surveillance, Epidemiology and End Results (SEER) program, Chaturvedi et al \[[@B3]\] conclusively demonstrated that HPV-positive OPSCC has increased markedly (225%) over the last three decades. Improved survival for patients with HPV-positive OPSCC was reported and our results agree with this finding. Patients tend to be younger, non-smokers, and non-drinkers with low rates of comorbid illness \[[@B3],[@B5],[@B6]\]. The observed high cure rates in this high functioning cohort of younger patients has led to an increased emphasis on post-treatment quality of life, as treatment side effects will potentially need to be endured for decades. Consequently, several studies have been initiated with the goal of the long-term sequelae of therapy for patients with HPV-positive OPSCC, such as the substitution of cetuximab for cisplatin in RTOG-1016.

However, a fraction of these patients still relapse and succumb to disease following conventional therapy. Ang et al \[[@B5]\] demonstrated that 21.2% of patients with HPV-positive tumors relapsed within 3 years, with 13.6% of these cases due to locoregional recurrence, and 8.7% due to the development of distant metastases. The biological reasons for this difference in treatment effectiveness are poorly understood. A partial explanation may be the specific HPV type implicated. In cervical cancer, HPV types 18 and 58 are associated with a poorer prognosis, while HPV-31 portends improved survival compared with HPV-16 \[[@B11]-[@B13]\]. To date only one study has demonstrated investigated a differential response or clinical presentation by HPV type in head and neck cancer. Rautava et al., retrospectively analyzed 106 patients with tumors from multiple head and neck sites including 31 oropharyngeal patients \[[@B14]\]. HPV genotyping was performed with a Luminex based Multimetrix® genotyping kit. In contrast with most studies, they found a very high rate of infection in non-oropharyngeal sites including the oral cavity (76%) and larynx (40%), as well as very high rate of co-infection (44%) and the presence of low-risk subtypes 6 and 11 (20%) \[[@B2],[@B15]\]. HPV was not found to be predictive of survival and there was no difference in outcome based on HPV type \[[@B14]\].

Although limited conclusions can be drawn given the small numbers of HPV types other than HPV-16 in our cohort, our data suggests that HPV-16 cancers may present more frequently with lymph node metastases and may have a poorer outcome compared with non-16 high-risk HPV types. Given the low frequency of HPV-positive OPSCC presentations that are not due to HPV-16, a very large multi-institutional series with HPV genotyping would need to be assembled in order to answer this question definitively.

A tremendous step forward in the battle against the multiple cancers caused by HPV is the implementation of HPV vaccination programs worldwide. The quadrivalent HPV vaccine is highly effective in preventing benign and precancerous lesion lesions due to HPV types 6, 11, 16 and 18 including cervical and anal dysplasia \[[@B16],[@B17]\]. Due to the significant lag time between infection and the development of malignancy, it will take decades to determine if these vaccines are effective in preventing anogenital and head and neck cancers. Indeed, most individuals develop HPV infection in their teens and twenties \[[@B18]\], however the average age of diagnosis of HPV-positive patients in our study was 58 years (range, 43--86). Due to this significant time gap as well as low rates of use of this vaccine in both males and females, the burden of HPV-related cancers will be an important clinical problem for the foreseeable future.

HPV-positive cancers are fundamentally distinct from traditional tobacco and alcohol related cancers \[[@B2]\]. Viral oncogenes E6 and E7 cause the degradation of wild-type p53 and pRb, respectively, while p16 is overexpressed. This is in contrast to frequent mutations of p53 and loss of p16 seen in conventional head and neck cancer \[[@B2]\]. The differences between HPV-positive and conventional head and neck cancers was further highlighted in two landmark papers by Stransky and Agrawal that reported large-scale whole exome sequencing of head and neck cancers \[[@B19],[@B20]\]. These studies revealed approximately a two to four-fold increase in number of mutations in HPV-negative compared with HPV-positive cancers and confirmed the differences in p53 and p16 outlined above. Despite these differences, there were significant overlaps in the mutational profiles of the two cancer types, including mutations in the NOTCH receptors (NOTCH1-3), HRAS, and PIK3CA that were seen in both HPV-positive and negative disease. Potentially, high-throughput technologies including expression microarrays, RNA-seq, and exome sequencing of large cohorts of HPV-positive OPSCC can identify biomarkers of local, regional and distant relapse as well as biological differences between cancers due to different HPV types. Patients at high-risk of failure could undergo treatment intensification with the goal of increasing survival, while low-risk patients could have their treatment de-intensified in order to optimize post-treatment quality of life. This would be a significant step towards customized care for patients with HPV-positive HNSCC.

Conclusions
===========

HPV infection is the etiologic factor for a significant proportion of OPSCC in Southwestern Ontario as has been observed worldwide. The majority of cases are attributable to HPV-16, while other high-risk subtypes are responsible for the remainder. HPV-16-positive OPSCC may present at a more advanced stage than those due to other high-risk HPV types. Larger studies are required to confirm this observation and determine if different HPV types influence prognosis.
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